Clear cell renal cell carcinoma+1
RecruitingStudy of XL092 and belzutifan combination therapy in people with clear cell kidney cancer who had disease return during or after immunotherapy treatment
Study of XL092 and belzutifan combination therapy in people with clear cell kidney cancer who had disease return during or after immunotherapy treatment
- Disease:Clear cell renal cell carcinomaRenal cell carcinoma
- Substances:BelzutifanN-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
France- Participants:18–64 years · 65+ years
- Substances:Belzutifan







